Deals
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
FEATURED STORIES
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
The $7 billion transaction by Datavant with Ciox Health will be the nation’s largest “neutral and secure health data ecosystem.”
Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
Unicorn Hunters is a new Internet reality show where startup companies can pitch a group of well-known panelists dubbed the “Circle of Money” which allows for a kind of crowdsourced funding appeal.
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
It didn’t take too long before a lawsuit was filed over Bristol Myers Squibb’s failure to meet a deadline for a $9 Contingent Value Rights agreement tied to the company’s merger with Celgene.
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies that will be focused on taking biotech companies public.
MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here’s everything you need to know about this billion dollars deal.